Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

I think I disagree with your intereptation. Are you saying all patients are followed for 16 weeks after their last visit? If so, that is not my understanding.

The way I interpret the collection and assessment of endpoints is that documentation of conditions start at baseline(first review of patient prior to treatment) with most endpoints final measurements taken at end of treatment(12 weeks) or at final visit((16 weeks, which is 4 weeks from end of treatment)).

Secondary endpoints #s 8&9, plasma concentrations of prurisol and abacavir respectively, have a time frame of 4 weeks and were to be measured in a subset(not defined) of patient.

They announced the final patient visit(no more follow up) 107 days ago on 12/21/17(15.28 weeks ago).


ps- what do mean by data treatment?